[EGRX] Eagle Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 730.08 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 80.93 Change: 5.35 (7.08%)
Ext. hours: Change: 0 (0%)

chart EGRX

Refresh chart

Strongest Trends Summary For EGRX

EGRX is in the medium-term up 40% in 2 years. In the long-term down -36% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was found

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding15.64 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 526.88% Sales Growth - Q/Q548.38% P/E
P/E To EPS Growth P/S14.45 P/BV7.1 Price/Cash Per Share
Price/Free Cash Flow-52.57 ROA1.66% ROE2.09% ROI
Current Ratio4.8 Quick Ratio4.72 Long Term Debt/Equity Debt Ratio0.26
Gross Margin71.95% Operating Margin2.84% Net Profit Margin4.26% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities55.29 M Cash From Investing Activities3.95 M Cash From Operating Activities17.96 M Gross Profit30.36 M
Net Profit19.7 M Operating Profit20.09 M Total Assets129.93 M Total Current Assets129.79 M
Total Current Liabilities27.05 M Total Debt Total Liabilities27.05 M Total Revenue36.31 M
Technical Data
High 52 week67.49 Low 52 week36.72 Last close61.99 Last change2.07%
RSI86.41 Average true range1.81 Beta1.24 Volume253.51 K
Simple moving average 20 days6.76% Simple moving average 50 days7.94% Simple moving average 200 days20.46%
Performance Data
Performance Week5.28% Performance Month5.5% Performance Quart13.89% Performance Half23.98%
Performance Year3.08% Performance Year-to-date53.86% Volatility daily1.68% Volatility weekly3.75%
Volatility monthly7.68% Volatility yearly26.62% Relative Volume311.49% Average Volume149.42 K
New High New Low

News

2020-06-03 03:31:30 | Edited Transcript of EGRX earnings conference call or presentation 11-May-20 12:30pm GMT

2020-05-26 16:30:00 | Eagle Pharmaceuticals to Present at June Investor Conferences

2020-05-22 16:05:00 | Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

2020-05-14 11:50:00 | Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Analysts Just Slashed This Year's Estimates

2020-05-12 16:30:00 | Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

2020-05-11 12:30:48 | Eagle Pharmaceuticals Inc EGRX Q1 2020 Earnings Call Transcript

2020-05-11 08:35:12 | Eagle Pharmaceuticals EGRX Q1 Earnings Surpass Estimates

2020-05-11 08:14:14 | Eagle Pharmaceuticals: Q1 Earnings Insights

2020-05-11 07:22:03 | A Look At The Fair Value Of Eagle Pharmaceuticals, Inc. NASDAQ:EGRX

2020-05-11 06:50:00 | Eagle Pharmaceuticals Reports First Quarter 2020 Results

2020-05-08 08:41:12 | Why Eagle Pharmaceuticals EGRX Might Surprise This Earnings Season

2020-05-07 06:07:10 | 3 Medical Product Stocks Set to Beat This Earnings Season

2020-05-04 06:50:00 | Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration "FDA"

2020-04-29 16:30:00 | Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020

2020-04-28 12:33:04 | Earnings Preview: Eagle Pharmaceuticals EGRX Q1 Earnings Expected to Decline

2020-04-28 06:50:00 | Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA bendamustine hydrochloride injection

2020-04-16 17:24:10 | Covid Report: Gilead Pops On Promising Sneak Peek For Coronavirus Drug

2020-04-16 06:50:00 | Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® dantrolene sodium Against Coronavirus SARS-CoV-2

2020-04-11 09:25:13 | What Is Eagle Pharmaceuticals's NASDAQ:EGRX P/E Ratio After Its Share Price Rocketed?

2020-03-30 06:50:00 | Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation

2020-03-22 15:34:06 | Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT

2020-03-10 07:55:20 | What Is Eagle Pharmaceuticals's NASDAQ:EGRX P/E Ratio After Its Share Price Tanked?

2020-03-02 08:15:01 | Eagle Pharmaceuticals EGRX Surpasses Q4 Earnings and Revenue Estimates

2020-03-02 06:50:00 | Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results

2020-02-24 12:30:05 | Earnings Preview: Eagle Pharmaceuticals EGRX Q4 Earnings Expected to Decline

2020-02-19 16:30:00 | Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020

2020-02-13 07:50:01 | Eagle Pharmaceuticals NASDAQ:EGRX Has A Pretty Healthy Balance Sheet

2020-02-10 09:54:00 | Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ Pemetrexed for Injection

2020-01-13 06:50:00 | Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania

2020-01-09 08:40:01 | Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

2020-01-09 06:50:00 | Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke

2020-01-08 10:18:03 | Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

2020-01-08 08:16:25 | Is Eagle Pharmaceuticals, Inc.'s NASDAQ:EGRX ROE Of 15% Concerning?

2020-01-07 09:25:00 | Tyme stock rises on Eage collaboration for cancer drug

2020-01-07 07:20:00 | Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer

2020-01-06 06:50:00 | Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury

2019-12-23 06:50:00 | Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

2019-12-16 06:50:00 | Eagle Pharmaceuticals Granted Orphan Drug Designation for RYANODEX dantrolene sodium for Treatment of Organophosphate Exposure Nerve Agents

2019-12-13 14:53:00 | Eagle Pharmaceuticals Reaches Settlement Agreement with Eli Lilly for PEMFEXY pemetrexed for injection

2019-12-11 11:25:36 | Eagle Pharmaceuticals Inc EGRX: Are Hedge Funds Right About This Stock?

2019-12-09 06:50:00 | Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate

2019-12-03 08:45:20 | If You Had Bought Eagle Pharmaceuticals NASDAQ:EGRX Stock Five Years Ago, You Could Pocket A 336% Gain Today

2019-11-20 06:50:00 | Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference

2019-11-18 21:32:30 | Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT

2019-11-14 06:50:00 | Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors

2019-11-12 08:15:01 | Eagle Pharmaceuticals EGRX Q3 Earnings and Revenues Lag Estimates

2019-11-12 06:51:00 | Eagle Pharmaceuticals Reports Third Quarter 2019 Results

2019-11-12 06:50:00 | Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage

2019-11-09 14:26:20 | Do Hedge Funds Love Eagle Pharmaceuticals Inc EGRX?

2019-11-05 10:31:03 | Analysts Estimate Eagle Pharmaceuticals EGRX to Report a Decline in Earnings: What to Look Out for